| Symbol | XBIT |
|---|---|
| Name | XBIOTECH INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 5217 WINNEBAGO LANE, AUSTIN, Texas, 78744, United States |
| Telephone | +1 512 386-2900 |
| Fax | — |
| — | |
| Website | http://www.xbiotech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001626878 |
| Description | XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States. Additional info from NASDAQ: |
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
Read moreXBiotech lance un essai clinique de phase II visant à évaluer le vilamakitug dans le traitement de la spondylarthrite axiale active
Read moreXBiotech startet klinische Phase-II-Studie zur Bewertung von Vilamakitug bei der Behandlung der aktiven axialen Spondyloarthritis
Read moreNew Form 10-K/A - XBiotech Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001171843-26-002814 <b>Size:</b> 634 KB
Read moreNew Form 10-K - XBiotech Inc. <b>Filed:</b> 2026-03-13 <b>AccNo:</b> 0001171843-26-001561 <b>Size:</b> 6 MB
Read moreNew Form S-8 - XBiotech Inc. <b>Filed:</b> 2026-03-11 <b>AccNo:</b> 0001171843-26-001492 <b>Size:</b> 228 KB
Read moreRademaker Craig Evan 🟢 acquired 92.1K shares (1 derivative) of XBiotech Inc. (XBIT) at $2.64 Transaction Date: Oct 01, 2025 | Filing ID: 276344
Read moreKuendig Thomas Martin 🟢 acquired 79.1K shares (1 derivative) of XBiotech Inc. (XBIT) at $2.64 Transaction Date: Oct 01, 2025 | Filing ID: 276336
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06526377 | Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy | Phase2 | Axial Spondyloarthritis | Not_Yet_Recruiting | 2026-09-01 | 2028-09-01 | ClinicalTrials.gov |
| NCT06590090 | Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | Phase2 | Rheumatoid Arthritis | Not_Yet_Recruiting | 2026-07-15 | 2027-07-15 | ClinicalTrials.gov |
| NCT05363891 | Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis | Phase2 | Rheumatoid Arthritis | Completed | 2023-08-08 | 2024-10-31 | ClinicalTrials.gov |
| NCT05098080 | Hutrukin to Analyze Safety and PK in Healthy Volunteers | Phase1 | Pharmacokinetics | Completed | 2023-04-10 | 2024-04-05 | ClinicalTrials.gov |
| NCT05363917 | Natrunix Versus Methotrexate in Rheumatoid Arthritis | Phase2 | Rheumatoid Arthritis | Unknown | 2022-06-15 | 2023-02-15 | ClinicalTrials.gov |
| NCT05099510 | Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers | Phase1 | Pharmacokinetics | Completed | 2022-01-19 | 2022-08-08 | ClinicalTrials.gov |
| NCT04825288 | XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancre… | Phase1 | Pancreatic Cancer | Completed | 2021-05-27 | 2025-06-10 | ClinicalTrials.gov |
| NCT03659201 | Efficacy and Safety of Neosil on Chronic Effluvium | Phase4 | Chronic Telogen Effluvium | Completed | 2018-09-03 | 2020-03-30 | ClinicalTrials.gov |
| NCT02357966 | Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacte… | Phase1 | Staphylococcus Aureus Bacteremia | Completed | 2015-05-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT00479947 | Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment… | Phase1 | Vaginal Candidiasis | Unknown | 2007-05-01 | 2007-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05099510 |
| Natrunix | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05099510 |
| Phase II: Placebo | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT04825288 |
| Phase II: XB2001 1000 mg | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT04825288 |
| Phase I: XB2001 1000 mg | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT04825288 |
| Phase I: XB2001 500 mg | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT04825288 |
| Phase I: XB2001 250 mg | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT04825288 |
| placebo | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| vilamakitug | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| placebo | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| vilamakitug | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| placebo | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| vilamakitug | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| placebo | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| vilamakitug | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| placebo | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| vilamakitug | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| placebo | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| vilamakitug | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| placebo | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| vilamakitug | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| placebo | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| vilamakitug | Other | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14) | Other | Phase PHASE1 | Vaginal Candidiasis | UNKNOWN | NCT00479947 |
| Probiotics (Natural product) | Other | Phase PHASE1 | Vaginal Candidiasis | UNKNOWN | NCT00479947 |
| Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14) | Other | Phase PHASE1 | Vaginal Candidiasis | UNKNOWN | NCT00479947 |
| Probiotics (Natural product) | Other | Phase PHASE1 | Vaginal Candidiasis | UNKNOWN | NCT00479947 |
| Neosil | Other | Phase PHASE4 | Chronic Telogen Effluvium | COMPLETED | NCT03659201 |
| Pantogar | Other | Phase PHASE4 | Chronic Telogen Effluvium | COMPLETED | NCT03659201 |
| Neosil complete | Other | Phase PHASE4 | Chronic Telogen Effluvium | COMPLETED | NCT03659201 |
| Neosil | Other | Phase PHASE4 | Chronic Telogen Effluvium | COMPLETED | NCT03659201 |
| Pantogar | Other | Phase PHASE4 | Chronic Telogen Effluvium | COMPLETED | NCT03659201 |
| Neosil complete | Other | Phase PHASE4 | Chronic Telogen Effluvium | COMPLETED | NCT03659201 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | UNKNOWN | NCT05099510 |
| NatrunixTM | Other | Phase PHASE1 | Pharmacokinetics | UNKNOWN | NCT05099510 |
| Natrunix placebo with MTX (+folate) | Other | Phase PHASE2 | Rheumatoid Arthritis | UNKNOWN | NCT05363917 |
| Natrunix with MTX placebo (+folate) | Other | Phase PHASE2 | Rheumatoid Arthritis | UNKNOWN | NCT05363917 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05098080 |
| Hutrukin | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05098080 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT05363891 |
| Natrunix | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT05363891 |
| XB2001 or Placebo | Other | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04825288 |
| Placebo plus standard IV antibiotic treatment: Phase II | Drug | Phase PHASE1 | Staphylococcus Aureus Bacteremia | COMPLETED | NCT02357966 |
| 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | Drug | Phase PHASE1 | Staphylococcus Aureus Bacteremia | COMPLETED | NCT02357966 |
| Placebo plus standard IV antibiotic treatment | Drug | Phase PHASE1 | Staphylococcus Aureus Bacteremia | COMPLETED | NCT02357966 |
| 514G3 (40 mg/kg) plus standard IV antibiotic treatment | Drug | Phase PHASE1 | Staphylococcus Aureus Bacteremia | COMPLETED | NCT02357966 |
| 514G3 (10 mg/kg) plus standard IV antibiotic treatment | Drug | Phase PHASE1 | Staphylococcus Aureus Bacteremia | COMPLETED | NCT02357966 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment | Drug | Phase PHASE1 | Staphylococcus Aureus Bacteremia | COMPLETED | NCT02357966 |
| Methotrexate (MTX) | DRUG | Phase PHASE2 | Rheumatoid Arthritis | NOT_YET_RECRUITING | NCT06590090 |
| Natrunix 400 mg | BIOLOGICAL | Phase PHASE2 | Rheumatoid Arthritis | NOT_YET_RECRUITING | NCT06590090 |
| Natrunix placebo with MTX (+folate) | DRUG | Phase PHASE2 | Rheumatoid Arthritis | UNKNOWN | NCT05363917 |
| Natrunix with MTX placebo (+folate) | DRUG | Phase PHASE2 | Rheumatoid Arthritis | UNKNOWN | NCT05363917 |
| Natrunix | DRUG | Phase PHASE2 | Axial Spondyloarthritis | NOT_YET_RECRUITING | NCT06526377 |
| NatrunixTM | BIOLOGICAL | Phase PHASE1 | Pharmacokinetics | UNKNOWN | NCT05099510 |
| Placebo | DRUG | Phase PHASE2 | Rheumatoid Arthritis | NOT_YET_RECRUITING | NCT06590090 |
| Hutrukin | BIOLOGICAL | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05098080 |
| XB2001 or Placebo | BIOLOGICAL | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04825288 |
| Placebo plus standard IV antibiotic treatment: Phase II | OTHER | Phase PHASE1 | Staphylococcus Aureus Bacteremia | COMPLETED | NCT02357966 |
| 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | BIOLOGICAL | Phase PHASE1 | Staphylococcus Aureus Bacteremia | COMPLETED | NCT02357966 |
| Placebo plus standard IV antibiotic treatment | OTHER | Phase PHASE1 | Staphylococcus Aureus Bacteremia | COMPLETED | NCT02357966 |
| 514G3 (40 mg/kg) plus standard IV antibiotic treatment | BIOLOGICAL | Phase PHASE1 | Staphylococcus Aureus Bacteremia | COMPLETED | NCT02357966 |
| 514G3 (10 mg/kg) plus standard IV antibiotic treatment | BIOLOGICAL | Phase PHASE1 | Staphylococcus Aureus Bacteremia | COMPLETED | NCT02357966 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment | BIOLOGICAL | Phase PHASE1 | Staphylococcus Aureus Bacteremia | COMPLETED | NCT02357966 |